New York Life Investment Management LLC Purchases 375 Shares of Repligen Co. (NASDAQ:RGEN)

New York Life Investment Management LLC raised its position in Repligen Co. (NASDAQ:RGEN) by 6.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 5,904 shares of the biotechnology company’s stock after acquiring an additional 375 shares during the period. New York Life Investment Management LLC’s holdings in Repligen were worth $1,062,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of RGEN. Artisan Partners Limited Partnership grew its position in Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after purchasing an additional 157,807 shares during the period. Wellington Management Group LLP grew its holdings in shares of Repligen by 2.1% during the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock valued at $222,075,000 after buying an additional 29,215 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Repligen by 0.4% during the fourth quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock worth $127,611,000 after acquiring an additional 2,590 shares in the last quarter. Parnassus Investments LLC bought a new stake in shares of Repligen during the third quarter worth about $87,475,000. Finally, Northern Trust Corp lifted its position in Repligen by 2.4% in the 3rd quarter. Northern Trust Corp now owns 471,919 shares of the biotechnology company’s stock valued at $75,040,000 after acquiring an additional 11,204 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 0.2 %

Shares of RGEN stock opened at $167.72 on Wednesday. The business has a 50-day moving average price of $179.84 and a two-hundred day moving average price of $174.62. The firm has a market cap of $9.37 billion, a P/E ratio of 670.91, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same quarter in the previous year, the firm posted $0.64 earnings per share. The company’s revenue was down 17.1% compared to the same quarter last year. Equities analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on RGEN shares. JPMorgan Chase & Co. decreased their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Finally, KeyCorp boosted their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $197.75.

Insider Transactions at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,597 shares of company stock worth $5,039,532. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.